To Study the Effects of Mango Ingestion in T2DM and Non-diabetic Subjects.

Sponsor
Diabetes Foundation, India (Other)
Overall Status
Completed
CT.gov ID
NCT06055582
Collaborator
Indian Council of Medical Research (Other)
130
1
2
12.6
10.3

Study Details

Study Description

Brief Summary

T2DM patient will be recruited from endocrine OPD

  1. Clinical History and Examination:

  2. General Physical Examination:

  • Height (cm)

  • weight (kg)

  • BMI (kg/m2)

  • Blood Pressure (mmHg)

  1. Anthropometry: Circumferences and skinfold thickness will be recorded for the patients in the following manner.
Circumferences:
  • Waist circumference (cm)

  • Hip circumference (cm)

  • Mid-arm circumference (cm)

  • Mid-thigh circumference (cm)

  1. Skin fold thickness: Skin fold thickness will be measured by using (LANGE skin fold calipers) (to nearest of 1 mm) at the following sites
  • Biceps (mm)

  • Triceps (mm)

  • Thigh (mm)

  • Calf (mm)

  • Sub scapular (mm)

  • Supra-iliac (mm)

  • Anterior axillary fold. (mm)

  1. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits
  • Blood glucose (mg/dL)

  • HbA1c (%)

  • Serum insulin (μIU/mL)

  • Total Cholestrol (mg/dl)

  • Triglyceride (mg/dl)

  • Fructosamine (umol/L)

  • Adiponectin (µg/ml) -- HOMA-IR

  1. Body Composition Analysis (TANITA)
Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Bread
  • Dietary Supplement: Mango
N/A

Detailed Description

  1. Phase I: Exploratory Acute Phase- Stratified randomized study
  • Study population: 2 groups; patients with T2DM and non-diabetic subjects n=45 (20 T2DM subject, 25 non-diabetic subjects).

  • Study groups: 3 groups; OGTT (n=5), mango (n=30), bread (n=10) Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.

Procedure for Phase I:

After measuring baseline glucose level on empty stomach, three groups will be given their respective standardized food item and blood samples will be drawn every half an hour upto 2 hours of ingestion at (minutes): 0, 30, 60, 90 and 120. Fingertip capillary blood will be used for the estimation of blood glucose using a glucometer of contour brand.

  1. Phase II: Exploratory Sub-Acute Phase- Two randomized cross over study
  • Study population: 2 groups; patients with T2DM and non-diabetic subjects, n=50 (25 in each study population group)

  • Study groups: 2 groups; mango (n=30), bread (n=20) Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.

Procedure for Phase II:
  1. Continuous glucose monitoring system (CGMS): It will be affixed for 3 days.

  2. The research team will be contacting the study subjects every day for any discomfort due to CGMS device or diet.

  3. On day 4 study subjects will be called to the study site and CGMS will be removed and data will be transferred to the study records.

  4. Study subjects will be asked to maintain a food diary and record the foods consumed during the entire period of 3 days.

  5. The subjects will also be asked to fill questionnaire of dietary assessment on Day 1 and Day 4 for per schedule of assessments.

  6. Phase III: Confirmatory Chronic Phase- Randomized controlled parallel arm study

  • Study population: patients with T2DM, n=35

  • Study groups: 2 groups; mango (n=20), bread (n=15) Subjects in mango group will be further randomized into two different groups. Each group will be tested on a different variety of mango.

Procedure for Phase III:

Subjects will be given glucometers and will be asked to monitor blood glucose at fasting state and after standard breakfast meal at baseline, at day 30 and day 60 in both the study groups. The intermediate term effect of mango consumption and bread consumption will be assessed at baseline and at day 60 in terms of following investigations:

  1. Dietary assessment

  2. Physical activity (PA) assessment (GPAQ)

  3. Blood pressure

  4. Anthropometry measures

  5. Body composition

  6. Biochemical investigations

Study Design

Study Type:
Interventional
Actual Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Patients with T2DM and non-diabetic subjects were randomized into two food groups- mango and bread for 3 days, then after a 7 days washout period, the cross-over took place.Patients with T2DM and non-diabetic subjects were randomized into two food groups- mango and bread for 3 days, then after a 7 days washout period, the cross-over took place.
Masking:
None (Open Label)
Masking Description:
Patients were recruited from Fortis C-DOC OPD.
Primary Purpose:
Prevention
Official Title:
A Randomized Controlled Study to Compare Effects of Mango Ingestion on Glycemia (Glycemic Response, Continuous Glucose Monitoring and Fructosamine) Insulin Resistance and Body Composition in Patients With T2DM and Non-diabetic Subjects.
Actual Study Start Date :
Feb 11, 2022
Actual Primary Completion Date :
Feb 15, 2023
Actual Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Treatment - Mango

Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.

Dietary Supplement: Mango
250g of mango pulp of each mango variety was given to the subjects.
Other Names:
  • Safeda, Dushehri, Langra
  • Other: Controlled- Bread

    Subjects in bread group were given 81g (3 slices) harvest gold white bread as standard food in raw form.

    Dietary Supplement: Bread
    81g (3 slices) harvest gold white bread as standard food.

    Outcome Measures

    Primary Outcome Measures

    1. Outcome for all the phases will be as follows [Baseline, after six months of intervention]

      Fasting glucose (mg/dL)

    2. Postprandial blood glucose (mg/dL) [Baseline, after six months of intervention]

    3. Glycemic indices as per Continuous glucose monitoring system (CGMS) & HbA1c (%) [Baseline, after six months of intervention]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    -For patients with diabetes: Stable glycemic control on metformin or sulfonylurea for past 3 months and without any major complications and HbA1C less than 8%

    Exclusion Criteria:
    • Acute infections and advanced end-organ damage

    • History of hepatitis or pancreatitis, abnormal liver and renal functions

    • Recent (<3 months) changes in weight

    • Any known allergy to mangoes and bread

    • Subjects with hypothyroidism

    • On any drug causing weight gain or weight loss.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fortis CDOC Hospital New Delhi Delhi India 110048

    Sponsors and Collaborators

    • Diabetes Foundation, India
    • Indian Council of Medical Research

    Investigators

    • Principal Investigator: Anoop Misra, MD, Fortis CDOC Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr Anoop Misra, Director, Diabetes Foundation, India
    ClinicalTrials.gov Identifier:
    NCT06055582
    Other Study ID Numbers:
    • 5/9/1309/2020-Nut
    First Posted:
    Sep 26, 2023
    Last Update Posted:
    Sep 26, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr Anoop Misra, Director, Diabetes Foundation, India
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 26, 2023